MMP-2, MMP-14, and TIMP-2 could be considered interesting targets for potential therapeutic interventions due to their roles in the entry of monocytes to the CNS and the recovery of CNS lesions in patients with MS [60]. Here, TIMP2 is linked to myeloid sarcoma.